Maury Strauss Distinguished Public Lecture
Date: May 14, 2026
Time: 5:30 – 6:30 p.m. (5 p.m. Reception and hors d’oeuvres)
Virtual: Join via Zoom or live webcast
Since 2023, anti-amyloid immunotherapies have been approved by the United States Food and Drug Administration for the treatment of persons with very mild to mild symptomatic Alzheimer’s disease (AD). These amyloid-targeting treatments (ATTs) do not cure AD, but can slow the rate of cognitive and functional decline, thus prolonging the period in which the patient retains independence. However, benefit is optimal when AD is accurately diagnosed early in its symptomatic course. Early diagnosis has now been notably facilitated by the availability of accurate, acceptable, and accessible blood-based biomarker (BBM) tests for AD. Together, BBMs and ATTs usher in a new era in AD diagnosis and treatment.
This is a free event hosted by Dr. Michael Friedlander and the Fralin Biomedical Research Institute. For more information, please call 540-526-2059.
Date: May 14, 2026
Start Time: 5:00 pm — 6:30 pm
Organizer: Fralin Biomedical Research Institute